iSpecimen, Inc. (NASDAQ: ISPC) is engaged as an online marketplace for human biospecimens. Seeking to connect life scientists with healthcare providers that can access patients and specimens needed for medical research and discovery. Shares of the human biospecimen company are surging 91% through early trading on Monday, November 22, 2021. Over the past three months, iSpecimen has seen average daily volume of 67,150 shares. However, volume of 69.8 million shares or dollar volume of around $674.27 million, has already exchanged hands through early trading Monday.
Shares of iSpecimen are soaring after the company announced that it has been selected by the U.S. government and private researchers to provide human biospecimens for use in advanced COVID-19 research. The new research will specifically look for new insights into COVID-19’s transmissibility, variants, testing validity and more.
Over the past ten months, iSpecimen says it has been working closely with the U.S. Centers for Disease Control and Prevention (CDC) to assist government researchers with antibody development and guidance. During that time, iSpecimen sent 600 positive COVID-19 serum samples and 100 negative samples to the CDC for further testing and research. In addition to the CDC, iSpecimen has sent hundreds of biospecimens to COVID-19 researchers with the U.S. military.
The human biospecimens are collected across a wide range of geographies with varieties in ages, races and ethnicities. In some cases, the company has different forms of serum have been collected using nasal swabs, oral swabs, saliva, and blood testing.
“COVID-19 has claimed more than 5 million lives, and it will require a lot of additional research to control the pandemic and improve society’s ability to contend with future outbreaks of infectious diseases,” said iSpecimen Founder and CEO, Christopher Ianelli, MD, Ph.D. “We embrace the challenge and are gratified that researchers are coming to us for the specific biospecimens they need from the types of patients they’re focusing on.”
Disclosure: Neither Spotlight Growth nor its officers have any position or relationship with any companies mentioned in this article. No payment was made to create this article. This article should not be taken as a solicitation or recommendation to buy or sell any securities. Please conduct your own research and consult your financial advisor to determine your risk tolerance and investment path. We are not licensed brokers or investment advisors.
